NightHawk Biosciences, a subsidiary of Elusys Therapeutics, is a leading brand in the field of biosciences, specializing in immune-stimulatory and immune-derived therapies to combat infectious diseases. Their flagship product, the anthrax antitoxin obiltoxaximab, is licensed as ANTHIM® in the United States and Canada, and as NYXTHRACIS® in the United Kingdom and the European Union. This effective medical countermeasure is designed to mitigate the effects of anthrax exposure following a natural incident or intentional attack.

NightHawk Biosciences is not only dedicated to addressing anthrax, but they are also at the forefront of developing cutting-edge platform technologies to target emerging biological threats. Their ultimate mission is to provide biodefense solutions that offer fast, effective treatment and durable protection. With a commitment to defending tomorrow today, NightHawk Biosciences collaborates with partners to build a strong and innovative ecosystem.

Stay ahead of infectious diseases with NightHawk Biosciences